Case Report: Marked Survival Advantage of Two Colorectal Cancer Patients with Liver Metastases Treated with Vigil and FOLFOX-6

Colorectal cancer is the third most diagnosed cancer in the United States. Five-year survival rates remain low and many patients will develop liver metastasis. Vigil is an immunotherapy manufactured from autologous tumor cells and transfected ex vivo with a plasmid that encodes the GM-CSF gene and b...

Descripción completa

Detalles Bibliográficos
Autores principales: Barve, Vedin, Adams, Ned, Stanbery, Laura, Manning, Luisa, Horvath, Staci, Wallraven, Gladice, Bognar, Ernest, Barve, Minal, Nemunaitis, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539810/
https://www.ncbi.nlm.nih.gov/pubmed/34696309
http://dx.doi.org/10.3390/vaccines9101201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539810/
https://www.ncbi.nlm.nih.gov/pubmed/34696309
http://dx.doi.org/10.3390/vaccines9101201

Ejemplares similares